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Background/aim: This study aimed to evaluate the effects of certain maternal, fetal, and umbilical cord blood unit factors on storage
and/or discard incidence of collected cord blood units from perinatal medicine patients.
Materials and methods: A total of 273 cord blood units collected between January 2011 and December 2016 in the Division of
Perinatology of Hacettepe University Hospital were evaluated retrospectively in this study.
Results: Of the collected cord blood units, 53.8% (147/273) were stored. Infant birth weight, cord blood unit volume, total nucleated
cell count, and CD34+ cell count were statistically significantly different between the eligible and discarded cord blood unit groups (P <
0.001 for all). No cord blood units were discarded owing to contamination-related issues. The mean gestational age for pregnant women
whose umbilical cord blood was stored was 36.6 ± 1.0 weeks.
Conclusion: Infant birth weight, cord blood unit volume, total nucleated cell count, and CD34+ cell count were significantly different
between the eligible and discarded cord blood unit groups. The low rate of specimen storage was most likely because of the unique
characteristics of perinatal medicine patients. Physicians should choose appropriate donors for cord blood collection to increase the
rate of cord blood utilization.
Key words: Umbilical cord blood, cord blood bank, pregnancy

1. Introduction
Umbilical cord blood (CB) is a natural source of
hematopoietic stem cells (HSCs) and is an accepted
alternative to bone marrow for transplantation purposes
in a variety of diseases such as leukemia, congenital
immunodeficiencies, hereditary metabolic disorders,
hemoglobinopathies, and bone marrow failure syndromes
(1–4). Gluckman et al. reported the first successful CB
transplantation for Fanconi anemia in 1989 (5). Since
then, CB banks (CBBs) have been established worldwide
to provide suitable CB units (CBUs) for use in allogeneic
HSC transplantation (6,7).
CB has profound clinical advantages over human
leukocyte antigen (HLA)-matched bone marrow, such
as lower incidence of graft-versus-host disease (GVHD),
immediate availability for use, low risk of transmission of
infectious diseases, and better long-term immune recovery
and survival rates (8).

CB can be collected and stored in two different settings:
in public and private banks (7). Moreover, hybrid banks
have also been recently established. Public banks collect
altruistic CBUs and process, store, and release the product
for clinical programs. On the other hand, private CBBs
are profit-oriented institutions facilitating the collection
and storage of CB from families on demand, for future
autologous or family use, for a certain price (9). Both
public and private CBUs can be used for directed banking,
which is aimed at using stored sibling donor CB for family
members when a first-degree relative is diagnosed as having
a disease that can be cured using CB transplantation (10).
A high percentage of CB used clinically is released through
public banks, where storage of high-quality CB is ensured
by both national and international standards.
CBUs altruistically collected from consenting eligible
donors and stored at CBBs constitute a valuable source of a
biological product with high therapeutic value that would
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otherwise be a medical waste. Nonetheless, determination
of donor eligibility is crucial, especially for low-income
countries with limited resources. Unit volume, total
nucleated cell (TNC) count, number of CD34+ HSCs,
infant birth weight, gestational age at birth, fetal distress,
placental weight, previous live births, meconium-stained
amniotic fluid, mode of delivery, and collection technique
can affect the quality and eligibility of CBUs for storage
(11–20).
The aim of this study was to evaluate the maternal,
neonatal, and CBU parameters that affect the storage and
discard rates of collected CBUs from perinatal medicine
patients with poor obstetric histories but whose current
pregnancies were being successfully managed.
2. Materials and methods
A total of 273 CBUs collected between January 2011 and
December 2016 at the Division of Perinatology of Hacettepe
University Hospital were evaluated retrospectively in this
study. The required data were obtained from the Hacettepe
University Perinatal Medicine Database.
FACT-NetCord (Foundation for the Accreditation
of Cellular Therapy together with NetCord) is one
of the major authorities in CB banking that establish
international standards for CB banking quality control.
The Ankara University Cord Blood Bank is currently the
only FACT-NetCord-accredited public CBB in Turkey. This
CBB is accredited for all steps of CB banking, including
consent gathering and CB collection, processing, banking,
and release of unrelated donations. Hacettepe University
Hospital is accredited by FACT-NetCord only for CB
collection and in collaboration with Ankara University
Cord Blood Bank. Our study included CBUs donated
voluntarily by pregnant women who delivered at our
institution. CB collections for medically indicated families
were excluded from this study.
The inclusion criteria for CB collection at our
institution were as follows: 1) written maternal informed
consent; 2) absence of familial inherited diseases; 3)
negative hepatitis B, hepatitis C, HIV, and HTLV (human
T-cell leukemia virus type-I/II) serology; 4) gestational age
of ≥32 weeks at birth; 5) rupture of membranes <12 h; 6)
absence of clinical and/or laboratory findings suggesting
chorioamnionitis; 7) absence of prenatally detected
chromosomal anomalies and congenital abnormalities in
the fetus; 8) absence of placental abnormalities; 9) absence
of multiple gestations; 10) absence of maternal chronic
inflammatory diseases; and 11) absence of maternal
metabolic and immunological disorders. Pregnant women
who did not meet these criteria were excluded from CB
collection. The majority of the patients were perinatal
medicine patients with poor obstetric histories but whose
current pregnancies were being successfully managed.
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CB was collected during the third stage of labor before
delivery of the placenta by trained physicians (in utero).
The umbilical cord was clamped at two different locations
(5 cm and 7 cm from the newborn) about 15 s after
delivery and was cleaned with 70% alcohol and iodine (in
the case of vaginal deliveries). The umbilical cord was cut
between the clamps, and the newborn was separated. CB
was collected from the umbilical vein by using a 16-gauge
needle, with the help of gravity and gentle milking until the
blood flow stopped, into a sterile 350-mL collection bag
containing 25 mL of CPDA (citrate, phosphate, dextrose,
and adenine) anticoagulant. After the collection of CBUs,
the bags were transferred to the CBB within 1–2 h for
processing. Selected deliveries (mostly daytime cesarean
sections [CSs], Monday to Thursday) were used for CB
collection to avoid technical difficulties and problems
during transportation to the CBB.
CBUs were processed and cryopreserved provided that
1) the time to transfer from collection was <48 h, 2) the
total volume was >40 mL, 3) the TNC count was >10 ×
108, 4) the CD34+ cell count was >1.5 × 106, and 5) there
was no evidence of aerobic or anaerobic bacterial/fungal
growth.
The CBUs were attached to a Sepax kit (Biosafe, CS530.4) and installed onto a Sepax device (Sepax S-100) in
a closed system. The final volume for HSC-rich buffy coat
was set to 22 mL, and the hematocrit percentage of the
CBU was included in the device settings. Red blood cell
(RBC) depletion and plasma depletion were performed
fully automatically, and CBUs were separated into three
final fractions: HSC-rich buffy coat, CBU plasma, and
RBCs. A 2-mL volume from the buffy coat was reserved
for HLA typing, complete blood count analysis, and CD34
cell phenotyping. After the infusion of 5 mL of dimethyl
sulfoxide into the buffy coat, units with a final volume of
25 mL were frozen to –160 °C in a controlled-rate freezer
and transferred into a liquid nitrogen tank (vapor phase).
Our primary aim in this study was to evaluate the
maternal and neonatal factors affecting the CBU eligibility
and discard rate. All the included CBUs were grouped
into two categories: eligible CBUs and ineligible discarded
CBUs. Statistical analysis was conducted using SPSS 22
(IBM Corp., Armonk, NY, USA). Maternal age, gravidity,
gestational week at birth, maternal hemoglobin value at
birth, gestational week at birth, infant birth weight, fetal
sex, CBU volume, and TNC and CD34+ cell counts of the
CBUs were investigated in both the eligible and ineligible
groups. Descriptive statistics were presented for each
maternal, neonatal, and CBU parameter investigated.
The variables were analyzed using visual histograms,
probability plots, and analytical methods (Kolmogorov–
Smirnov/Shapiro–Wilk test) to determine whether they
were normally distributed. As the data were normally
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distributed, means and standard deviations were used.
The independent-samples t-test was used to compare
the parametric variables between the groups. Categorical
variables were compared using the chi-square test. An
overall P-value of <0.05 was considered statistically
significant.
Informed consent was obtained from all patients,
and the study protocol was approved by the Hacettepe
University Ethics Committee.
3. Results
A total of 147 deliveries were included in the eligible group
(53.8%) and 126 deliveries in the discarded group (46.2%).
The maternal characteristics, neonatal characteristics, and
CBU parameters of the donors in terms of mean, standard
deviation, minimum–maximum values, and P-values are
shown in the Table for the indicated groups.
There were no statistically significant differences
between groups in terms of the mean values calculated
for the parameters investigated: maternal age, gravidity,
parity, maternal hemoglobin value, and gestational week
at birth (P = 0.237, P = 0.156, P = 0.69, P = 0.51, and P =
0.26, respectively).
However, the mean values of infant birth weight,
CBU volume, TNC count, and CD34+ cell count were
statistically different between the groups (P < 0.001
for all). The means and standard deviations of infant
birth weight, CBU volume, TNC count, and CD34+ cell
count were 2996.94 ± 349.00 g, 104.12 ± 23.68 mL, 15.27
± 2.20 × 108, and 3.00 ± 0.84 × 106, respectively, for the
stored (eligible) group. On the other hand, the means and
standard deviations of infant birth weight, CBU volume,

TNC count, and CD34+ cell count were 2825.80 ± 364.30
g, 81.40 ± 26.32 mL, 6.39 ± 1.24 × 108, and 0.64 ± 1.78 ×
106, respectively, for the discarded group of CBUs. There
were 67 (45.6%) male and 80 (54.4%) female fetuses in the
eligible group. On the other hand, there were 71 (56.3%)
male and 55 (43.7%) female fetuses in the discarded group.
However, there was no statistically significant difference
between the groups in terms of fetal sex (P = 0.076).
More than 35,000 unrelated CBUs have been
distributed worldwide by public CBBs for allogeneic HSC
transplantation. The usage rate of CBUs at the Ankara
University CBB is 2% (30 of 1502) to date (until July
2018) (10 for related and 20 for unrelated transplantation
purposes), and 34.8% of these CBUs were collected at
Hacettepe University. For confidentiality reasons, the
Ankara University CBB is the only authority that keeps the
identities of the CBUs used for transplantation.
4. Discussion
CB can be collected using either in utero or ex utero
techniques. The ex utero method relies more on the
collectors’ and/or clinicians’ experience (21). The main
limitation of CBUs is the small collection volume, which
generally leads to low TNC and CD34+ cell counts, thus
restricting application to children and small-sized adult
patients (18). However, various strategies to increase
HSC content and the homing capacity of CBUs have been
developed and used successfully. Thus, CB is currently
one of the most promising “off-the-shelf ” products to
be used both in transplantation (pediatric/adult) and
regenerative medicine (22,23). In contrast to many
other CBBs worldwide, where CB collection is primarily

Table. Maternal, neonatal, and CBU parameters compared between the eligible and discarded groups.
CBB status
Eligible (147) (53.8%)

Discarded (126) (46.2%)

Variables

Mean ± SD

Range
Mean ± SD
(minimum–maximum)

Range
P-value
(minimum–maximum)

Maternal age (years)

31.1 ± 4.08

20–41

30.45 ± 4.88

21–45

0.237

Gravidity

3.0 ± 1.60

1–9

3.3 ± 1.47

1–7

0.156

Parity

0.81 ± 0.89

0–5

0.85 ± 0.84

0–3

0.69

Maternal Hb (g/dL)

10.45 ± 2.06

6–16

10.30 ± 1.90

6–14

0.51

Gestational age at birth (weeks) 36.70 ± 1.07

35–40

36.60 ± 0.86

34–38

0.26

Infant birth weight (g)

2996.94 ± 349.00

1470–4120

2825.80 ± 364.30 1640–4100

<0.001

CBU volume (mL)

104.12 ± 23.68

54–212

81.40 ± 26.32

<0.001

22–152

TNC (×10 ) count

15.27 ± 2.20

10–18.4

6.39 ± 1.24

2.10–9.40

<0.001

CD34+ cell count (×106)

3.00 ± 0.84

1.52–4.50

0.64 ± 1.78

0.20–1.30

<0.001

8

SD: Standard deviation, CBB: cord blood bank, CBU: umbilical cord blood unit, Hb: hemoglobin, TNC: total nucleated cells.
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performed by midwifes, nurses, or well-trained CBB staff,
obstetricians perform the collections in Turkey. Thus, the
in utero technique is almost always preferred, as it is more
practical, cheaper, and easier to perform (24).
CB has been considered an alternative source of HSCs
needed for the treatment of certain diseases (2). Although it
has advantages over bone marrow, such as lower incidence
of GVHD, immediate availability for use, low risk of
transmissible infectious diseases, and better long-term
immune recovery and survival (8), the main drawback for
the use of CBUs in the HSC transplantation setting is the
low number of TNCs and CD34+ cells owing to the small
collection volumes (18). Because public banks rely on
financial support from the government, distinctive donor
eligibility determination is of high importance, particularly
for low-income countries with limited resources (25).
Furthermore, the small number of collected cells restricts
the application of the procedure to children and smallsized adults (18). However, progress in the enhancement of
cell counts by using various stimulation methods seems to
be a good innovation in this field and is expected to widen
the spectrum of transplantation patients (22,23). Thus, it is
important to select suitable donors for CB collection and
storage to facilitate optimal use.
Faivre et al. examined several variables related to the
parturient, pregnancy, labor, delivery, collection, the
newborn, the umbilical cord, and the placenta in their
comprehensive review that included 71 related articles (26).
Maternal age at delivery was assessed in 28 of 71 articles,
and it was found not to be associated with favorable CBU
collection parameters in most of the studies.
Additionally, Faivre et al. indicated that iron-related
maternal blood variables did not seem to affect the CBU
quality according to the literature they reviewed (26).
They also evaluated the effect of gestational age at birth
by reviewing 24 articles. In 17 articles, no correlation was
found between CBU volume and gestational age. However,
a positive correlation was found in 7 articles. A positive
correlation was also shown between older gestational age at
birth and TNC count in 22 individual studies. In contrast,
no significant correlation with CD34+ cells was reported
in 18 studies, and an inverse correlation was found in
11 articles. However, 3 studies observed a correlation
between CD34+ cells and older gestational age at birth.
Furthermore, an inverse relation was similarly reported
with colony-forming units (CFUs) in 5 articles (26).
In light of the literature, Faivre et al. recommended
to limit CBU collections after a defined gestational age
for cost-effectiveness issues. The effect of parity was also
another parameter evaluated in this review (26). In 25
articles, the researchers evaluated the impact of previous
births on CBU volumes, TNC count, CD34+ cell count,
and/or CFUs. Overall, no correlation was found between
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previous births and CBU quality, irrespective of the
variables tested. Although some studies showed a slight
increase of TNC and CD34+ cell counts in primiparous
women, the authors attributed these findings to the higher
rates of fetal stress due to longer delivery times. Thirtyseven studies assessed the effect of delivery type on CBU
parameters included in this review (26). CBU volume
was shown to be significantly higher with CS delivery,
and TNC counts were observed to be significantly higher
with vaginal delivery. Faivre et al. also reviewed 45 studies
that evaluated the effect of birth weight on CBU quality
(26). Although heavier birth weight was associated with
favorable CBU parameters in a vast majority of the studies,
no significant impact of fetal sex was shown.
Infant birth weight, CBU volume, TNC count, and
CD34+ cell count were statistically significantly different
between the groups in our study. The CS rate was very
high in our study population (269 of 273, 98.2%) because
physicians preferred CS cases for CB collection to avoid
technical difficulties and transfer problems. There were
3 vaginal deliveries in the eligible CBU group, whereas
only 1 vaginal birth was present in the ineligible discarded
group. These findings revealed that heavier infants, higher
volumes, and higher TNC and CD34+ cell counts were
associated with higher CB storage rates, compatible with
the current literature (11–15,18,19). However, there
were no statistically significant differences in the mean
values of the parameters investigated, including maternal
age, gravidity, parity, maternal hemoglobin value, and
gestational age at birth, between the groups (P = 0.237, P =
0.156, P = 0.69, P = 0.51, and P= 0.26, respectively).
We did not consider the influence of mode of delivery,
fetal distress, meconium-stained amniotic fluid, placental
weight, and collection techniques on CBB outcomes
because of lack of information. Selected deliveries (mostly
daytime CSs, Monday to Thursday) were used for CB
collection to avoid technical difficulties and problems in
transportation to the CBB. In our series, all CBUs were
collected in utero and only 53.8% of them were stored.
This low rate of specimen storage is most probably because
of the unique characteristics of the patients admitted
to the Division of Perinatal Medicine. The majority of
the patients were perinatal medicine patients with poor
obstetric histories but whose current pregnancies were
being successfully managed.
The mean gestational age for the pregnant women
whose CBs were stored was 36.6 ± 1.0 weeks. The study
population consisted of women with early term or
late preterm deliveries with poor obstetric history, as
mentioned earlier. We did not observe any microbiological
contamination, and the perinatal medicine staff seemed to
be more devoted to the collection process and collaborated
more easily than the obstetrics ward staff. Uncomplicated
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term deliveries are considered ideal for CB collection.
However, “successfully managed risky pregnancies” (like
in our cohort) should also be kept in mind, especially in
places with low CB collection costs. However, encouraging
more pregnant women to donate CB, increasing the
number of public CBBs, training medical staff for better
collection techniques, choosing term and heavier fetuses
for CB collection, facilitating CB collection even in
emergency deliveries, and increasing CB collection rates
in vaginal deliveries may increase the utilization rate of
CBUs for treatment. CB banking and CB collection are
relatively new issues in the daily practice of obstetricians
in Turkey. Additionally, more comprehensive studies are
needed about the quality assessment of CB collection
procedures that are carried out at various institutions in
Turkey. Thus, our study is a critical step for the evaluation
of various factors that affect the storage rate of CBUs, as
our institution is one of the leading national facilities for
CB collection.
To ensure successful treatment and the true realization
of the potential of CBUs, it is crucial that each and
every collection maintains the high quality defined in
international standards. Storing altruistic CBUs that
were selected according to the highest eligibility criteria

makes the products more cost-effective and beneficial
for the patients, preventing unnecessary costs from the
need to acquire the product from other international
CBBs. A well-organized national public bank such as the
Ankara University CBB is a perfect opportunity not only
for Turkish patients but also for international patients
worldwide.
The main strengths of our study were the relatively high
number of patients and the application of a standardized
procedure for all patients (same medical staff and same
conditions). However, the retrospective design, singlecenter experience, and homogeneity of the patients
(perinatal medicine patients with poor obstetric histories)
were the main limitations of our study.
In conclusion, infant birth weight, CBU volume,
TNC count, and CD34+ cell counts were statistically
significantly different between the eligible and discarded
CBU groups. Physicians should choose appropriate donors
for CB collection to increase the rate of CB utilization.
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